

Immutep

A second big pharma collaboration for efti

Immutep has entered into a clinical trial collaboration and supply agreement with Merck/Pfizer to investigate the combination of its APC activator eftilagimod alpha (efti) with avelumab in patients with advanced solid tumours. Avelumab is the big pharma pair's investigational anti-PD-L1 immune checkpoint inhibitor (ICI). We view the additional validation from big pharma is as a very positive development for Immutep, which could bring the added bonus of early identification of additional target indications. We maintain our valuation at A\$510m or A\$0.17/share.

Year end	Revenue (A\$m)	PBT* (A\$m)	EPS* (c)	DPS* (c)	P/E (x)	Yield (%)
06/17	4.1	(8.4)	(0.4)	0.0	N/A	N/A
06/18	6.9	(10.9)	(0.5)	0.0	N/A	N/A
06/19e	10.9	(6.8)	(0.2)	0.0	N/A	N/A
06/20e	2.8	(14.9)	(0.5)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding exceptional items.

Additional validation from big pharma

Immutep already has an ongoing clinical trial collaboration with the US-based Merck and Company (known as MSD outside the US), which is totally separate from Merck KGaA, including the TACTI-mel and TACTI-002 studies. It now has the additional validation of having a second big pharma team review the efti data and conclude that there is a potentially meaningful benefit from efti/ICI combination therapy. The encouraging results from the first three TACTI-mel cohorts included a 33% response rate from the start of efti/Keytruda combination therapy and 61% response rate from the start of the Keytruda monotherapy screening period.

Avelumab combination to be added to INSIGHT trial

The study of avelumab plus subcutaneous (SC) efti in patients with a range of advanced solid tumours will be included as an arm of the INSIGHT study (<u>NCT03252938</u>), which is underway at a single site in Germany. The combination would fit neatly into INSIGHT, which already includes arms investigating intratumoural and intraperitoneal administration of efti, as well as a third arm investigating SC efti in combination with chemo in solid tumours. This strategy should allow the efti/avelumab combination study to start before the end of CY18.

Competitive tension a potential added bonus

Having a deep level of engagement with two big pharma companies (or three counting Pfizer) could bring the added bonus of increased competitive tension when the time comes to negotiate a partnership deal for efti.

Valuation: Unchanged at A\$510m, 17c per share

Our valuation is unchanged at A\$510m, 17c/share (undiluted), or 12c/share after diluting for options and convertible notes. Our valuation includes a modest allowance for expansion of efti indications beyond the ongoing studies in breast, head and neck, melanoma and lung cancers. Gross cash at 30 June was A\$23.5m. We assume Immutep will receive a risk-adjusted US\$6m IMP731 milestone payment from GSK in FY19, which would extend its cash reach to the end of FY20.


Merck/Pfizer collaboration

Pharma & biotech

27 September 2018

Price	A\$0.048
Market cap	A\$145m
	US\$0.76/A\$
Gross cash (A\$m) at 30 June 2018	23.5
Shares in issue	3,026.1m
Free float	87%
Code	IMMX
Primary exchange	ASX
Secondary exchange	NASDAQ

Share price performance



Business description

Immutep is an ASX-listed biotech company focused on cancer immunotherapy. Its pipeline is based on four products using an LAG-3 immune control system: eftilagimod alpha for cancer chemoimmunotherapy, and partnered products IMP731 (GSK) and IMP701 (Novartis) and IMP761 (preclinical).

Next events

TACTI-mel data update including additional cohort	November
Initiate TACTI-002 Phase II	Q418
Fully recruit AIPAC breast cancer Phase II	Q418/Q119

Analysts

Dr Dennis Hulme	+61 (0)2 8249 8345
Maxim Jacobs	+1 646 653 7027
healthcare@edisongroup	o.com

Edison profile page

Immutep is a research client of Edison Investment Research Limited



Exhibit 1: Financial summary

A\$000s	2016	2017	2018	2019e	2020e
Year-end 30 June	IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS					
Revenue	1,949	4,117	6,854	10,898	2,778
R&D expenses	(7,060)	(7,526)	(9,990)	(10,990)	(10,440)
SG&A expenses	(6,983)	(4,347)	(7,242)	(7,459)	(7,683)
EBITDA	(12,093)	(7,756)	(11,435)	(7,551)	(15,345)
Operating Profit (before GW and except.)	(12,275)	(7,770)	(11,446)	(7,554)	(15,350)
Intangible Amortisation	(1,993)	(1,688)	(1,798)	(1,650)	(1,501)
Exceptionals	(47,468)	0	0	0	0
Operating Profit	(61,736)	(9,458)	(13,244)	(9,204)	(16,851)
Other	(1,716)	(752)	323	0	0
Net Interest	256	104	177	704	498
Profit Before Tax (norm)	(13,735)	(8,417)	(10,946)	(6,850)	(14,851)
Profit Before Tax (IFRS)	(63,196)	(10,105)	(12,744)	(8,500)	(16,352)
Tax	1,181	737	(2)	0	0
Profit After Tax (norm)	(12,554)	(7,680)	(10,948)	(6,850)	(14,851)
Profit After Tax (IFRS)	(62,015)	(9,368)	(12,746)	(8,500)	(16,352)
Average Number of Shares Outstanding (m)	2,016.6	2,072.5	2,079.7	3,026.1	3,026.1
EPS - normalised (c)	(0.6)	(0.4)	(0.5)	(0.2)	(0.5)
EPS - IFRS (c)	(3.1)	(0.5)	(0.6)	(0.3)	(0.5)
Dividend per share (c)	0.0	0.0	0.0	0.0	0.0
Gross Margin (%)	N/A	N/A	N/A	N/A	N/A
EBITDA Margin (%)	N/A N/A	N/A	N/A	N/A	N/A
	N/A N/A	N/A	N/A N/A	N/A N/A	N/A
Operating Margin (before GW and except.) (%)	IN/A	IN/A	IN/A	IN/A	IN/A
BALANCE SHEET					
Fixed Assets	20,883	19,045	18,356	16,715	15,223
Intangible Assets	20,852	19,020	18,329	16,680	15,178
Tangible Assets	32	24	26	36	45
Other	0	0	0	0	0
Current Assets	21,671	15,919	28,643	21,784	6,924
Stocks	0	0	0	0	0
Debtors	168	2,194	3,432	3,432	3,432
Cash	20,880	12,237	23,476	16,616	1,756
Other	623	1,488	1,736	1,736	1,736
Current Liabilities	(1,472)	(2,632)	(3,853)	(3,853)	(3,853)
Creditors	(1,444)	(2,589)	(3,664)	(3,664)	(3,664)
Short term borrowings	(0)	(0)	0	0	0
Short term leases	0	0	0	0	0
Other	(28)	(43)	(190)	(190)	(190)
Long Term Liabilities	(5,765)	(5,799)	(9,623)	(9,623)	(9,623)
Long term borrowings incl. conv. note	(5,027)	(5,779)	(6,646)	(6,646)	(6,646)
Long term leases	0	0	0	0	0
Other long term liabilities	(737)	(20)	(2,978)	(2,978)	(2,978)
Net Assets	35,317	26,532	33,522	25,022	8,670
CASH FLOW					
Operating Cash Flow	(11,594)	(8,611)	(7,954)	(7,551)	(15,345)
Net Interest	284	104	177	704	498
Tax	0	0	0	0	0
Capex	(27)	(7)	(12)	(12)	(13)
Acquisitions/disposals	130	0	0	0	0
Financing	27,229	(9)	18,898	0	0
Dividends	0	0	0	0	0
Other	0	0	(493)	0	0
Net Cash Flow	16,022	(8,522)	10,616	(6,859)	(14,860)
Opening net debt/(cash)	(5,251)	(15,852)	(6,458)	(16,830)	(14,000)
HP finance leases initiated	0	0	0	0	(0,010)
Other	(5,421)	(872)	(244)	0	0
Closing net debt/(cash)	(15,852)	(6,458)	(16,830)	(9,970)	4,889
Source: Immuten accounts. Edison Investment Research	(10,002)	(0,-00)	(10,000)	(0,010)	7,000

Source: Immutep accounts, Edison Investment Research



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the <u>Financial Conduct Authority</u>. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ US) is the US subsidiary of Edison and strategic commission. Edison Investment Research to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Immutep and prepared and issued by Edison for publication globally. All information used in the publication of this report. Opinions contained in this report represent those of the research department of Edison at the time of publications. The securities described in the Investment Research may not be eligible for sale in all jurisdicitons or to certain categories of investment. The securities described in the Investment Research may not be eligible for sale in all jurisdicitons or to certain categories of investment Adviser and the meaning of the Corporations Act 2010 for Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investment Advisers Act 1940 and corresponding state securities and Exchange Commission. Edison US relies upon the "publishiers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information networks (for use in their roles as financial advisers or brokers) and should not be construed in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for this designed to promote the independence of investment freesarch and is not subject to any prohibition on dealing adhead of the dissemination of investment tesearch and is not subject to any prohibition on dealing adhead of the dissemination of investment freesarch and is not subject to any prohibition on dealing adhead of the dissemination of investment freesarch and or in the topic of this document. This document is pro

Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom New York +1 646 653 7026 295 Madison Avenue, 18th Floor 10017, New York US Sydney +61 (0)2 8249 8342 Level 4, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia